Stock GCTK GLUCOTRACK, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials GlucoTrack, Inc.

Equities

GCTK

US45824Q6061

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
1.67 USD +0.60% Intraday chart for GlucoTrack, Inc. -4.02% +27.72%
Jul. 01 GlucoTrack, Inc. announced that it has received $0.1 million in funding CI
Jun. 20 Glucotrack Announces the Appointment of Andy Balo to Board of Directors CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 4.432 97.22 71.24 64.42 21.82 5.463
Enterprise Value (EV) 1 4.503 97.18 61.78 58.6 19.71 1.167
P/E ratio -0.11 x -26.4 x -17.8 x -15.8 x -4.92 x -0.68 x
Yield - - - - - -
Capitalization / Revenue 102 x 466 x - - - -
EV / Revenue 104 x 466 x - - - -
EV / EBITDA -0.59 x -28.1 x -20 x -14.7 x -4.47 x -0.16 x
EV / FCF -1.27 x -34.4 x -22.3 x -25.9 x -9.24 x -0.3 x
FCF Yield -78.5% -2.91% -4.49% -3.86% -10.8% -334%
Price to Book -24.6 x -69.2 x 7.94 x 12.5 x 17.8 x 1.71 x
Nbr of stocks (in thousands) 136 2,493 3,087 3,090 3,095 4,178
Reference price 2 32.50 38.99 23.07 20.85 7.050 1.308
Announcement Date 4/15/19 4/14/20 4/13/21 3/31/22 3/31/23 3/28/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.0435 0.2088 - - - -
EBITDA 1 -7.58 -3.455 -3.085 -3.998 -4.409 -7.091
EBIT 1 -7.639 -3.506 -3.132 -4.04 -4.432 -7.104
Operating Margin -17,564.85% -1,679.25% - - - -
Earnings before Tax (EBT) 1 -6.715 -3.516 -2.696 -4.067 -4.435 -7.097
Net income 1 -6.715 -3.516 -2.696 -4.067 -4.435 -7.097
Net margin -15,442.01% -1,684.28% - - - -
EPS 2 -308.2 -1.475 -1.300 -1.316 -1.433 -1.915
Free Cash Flow 1 -3.535 -2.825 -2.776 -2.265 -2.132 -3.902
FCF margin -8,128.73% -1,353.36% - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/15/19 4/14/20 4/13/21 3/31/22 3/31/23 3/28/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 0.07 - - - - -
Net Cash position 1 - 0.04 9.46 5.81 2.12 4.3
Leverage (Debt/EBITDA) -0.009386 x - - - - -
Free Cash Flow 1 -3.54 -2.83 -2.78 -2.27 -2.13 -3.9
ROE (net income / shareholders' equity) 223% 164% -71.2% -57.5% -139% -321%
ROA (Net income/ Total Assets) -405% -222% -33.5% -29.9% -63.7% -121%
Assets 1 1.658 1.581 8.058 13.59 6.967 5.869
Book Value Per Share 2 -1.320 -0.5600 2.910 1.670 0.4000 0.7700
Cash Flow per Share 2 0.0400 0.1700 3.180 1.960 0.7500 1.080
Capex 1 0.01 0.02 0.05 0.01 0 -
Capex / Sales 12.35% 11.22% - - - -
Announcement Date 4/15/19 4/14/20 4/13/21 3/31/22 3/31/23 3/28/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GLUCOTRACK, INC. Stock GlucoTrack, Inc.
+27.72% 9.15M
MODERNA, INC. Stock Moderna, Inc.
+22.10% 46.55B
LONZA GROUP AG Stock Lonza Group AG
+46.68% 41.84B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.12% 40.84B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+36.10% 32.95B
CELLTRION, INC. Stock Celltrion, Inc.
-6.30% 28.27B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+18.71% 27.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+46.15% 14.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+44.52% 13.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.19% 12.18B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GCTK Stock
  4. Financials GlucoTrack, Inc.